Optimizing long-term therapy for Parkinson disease: options for treatment-associated dyskinesia.
There is currently no satisfactory treatment for dyskinesia in patients with Parkinson disease because most antidyskinetic strategies have the effect of aggravating Parkinsonian symptoms, and most pharmacological strategies for reducing "off" periods have increased dyskinesia as a treatment complication. Therefore, physicians and patients often have to balance treatment of its effects on Parkinsonian symptoms and on dyskinesia. In patients with advanced Parkinson disease, it is often not possible to induce periods of good mobility without dyskinesia.
Stacy
Mark
M
Division of Neurology, Duke University Medical Center, Durham, NC 27705, USA. mark.stacy@duke.ed
Galbreath
Andrew
A
D000978:Antiparkinson Agents / Q000009:adverse effects*; D020820:Dyskinesias / Q000209:etiology*; D006801:Humans; D007980:Levodopa / Q000009:adverse effects*; D010300:Parkinson Disease / Q000188:drug therapy
D000978:Antiparkinson Agents; D007980:Levodopa